Tesamorelin is not a steroid. It is a synthetic peptide, a chain of 44 amino acids that mimics a hormone your brain naturally produces called growth hormone-releasing hormone (GHRH). Steroids and peptides are fundamentally different classes of molecules with different structures, different mechanisms, and different legal classifications.
What Tesamorelin Actually Is
Tesamorelin belongs to a class of drugs called GHRH analogs. It is a lab-made copy of the natural signaling molecule your hypothalamus uses to tell your pituitary gland to release growth hormone. The synthetic version has a small chemical modification at one end of the amino acid chain that prevents enzymes in your blood from breaking it down too quickly, making it last longer than the natural version.
Anabolic steroids, by contrast, are synthetic versions of testosterone or similar hormones built on a cholesterol-like ring structure. They directly flood your body with hormones or hormone-like compounds. Tesamorelin doesn’t do that. Instead, it nudges your pituitary gland to produce more of its own growth hormone through the signaling pathway your body already uses. This distinction matters because your body’s natural feedback loop stays intact: when growth hormone and IGF-1 levels rise high enough, your pituitary dials back production on its own, which limits the risk of excess.
Why People Confuse It With Steroids
The confusion is understandable. Tesamorelin reduces body fat, and anabolic steroids can change body composition too. Both show up in conversations about performance enhancement and anti-aging. But the similarity ends there. Steroids work by binding directly to androgen receptors in muscle and other tissues, promoting protein synthesis and masculinizing effects. Tesamorelin works upstream, at the level of the pituitary gland, stimulating your body’s own growth hormone output rather than replacing it with an external hormone.
The legal status reflects this difference. Anabolic steroids are classified as Schedule III controlled substances by the DEA, alongside testosterone and ketamine. Tesamorelin is not a controlled substance. It is a prescription medication, so you still need a doctor’s order to obtain it legally, but it doesn’t carry the same regulatory restrictions or criminal penalties associated with anabolic steroids.
What Tesamorelin Is Prescribed For
The FDA approved tesamorelin (sold as Egrifta) for one specific use: reducing excess abdominal fat in people with HIV-associated lipodystrophy. This is a condition where antiretroviral therapy causes abnormal fat accumulation around the organs in the abdomen. It is not approved for general weight loss, and the FDA specifically notes it has a “weight neutral effect,” meaning it targets visceral fat without significantly changing overall body weight.
In clinical trials, tesamorelin reduced visceral fat by about 15% over 26 weeks and 18% over 52 weeks. Nearly 70% of patients treated with tesamorelin achieved at least an 8% reduction in visceral fat area, compared to 33% of those on placebo. Among those who responded well, the average reduction in abdominal fat area was substantial and continued to improve with longer treatment.
How It’s Taken
Tesamorelin is injected subcutaneously, meaning just under the skin of the abdomen, once daily at a dose of 1.4 mg. You rotate injection sites across different areas of the abdomen, avoiding scar tissue, bruises, and the navel. This is another practical difference from most oral anabolic steroids or intramuscular testosterone injections.
Side Effects and Safety Profile
Side effects from tesamorelin are generally uncommon. When they do occur, the most frequent are injection site reactions, itching, joint pain, muscle pain, and mild swelling in the hands or feet. In pooled data from over 800 patients treated for up to a year, adverse event rates were similar between tesamorelin and placebo groups.
The more notable safety consideration involves blood sugar. Growth hormone naturally opposes insulin’s effects, so any treatment that raises growth hormone levels can potentially worsen glucose control. However, because tesamorelin works through the body’s own feedback system rather than flooding it with external hormone, the risk of hyperglycemia is lower than with direct growth hormone injections. A study in patients with type 2 diabetes found that the preserved IGF-1 feedback loop helps prevent the kind of excess growth hormone levels that cause glucose problems with exogenous hormone replacement.
Rare but potential concerns include glucose intolerance, hypersensitivity reactions, and the theoretical risk of stimulating growth of existing malignant tumors. Tesamorelin is also classified as unsafe during pregnancy due to potential developmental risks.
Tesamorelin vs. Growth Hormone Injections
People sometimes lump tesamorelin together with synthetic growth hormone (somatropin), but the two work differently. Growth hormone injections deliver the hormone directly into your body, bypassing the pituitary entirely. This can push growth hormone and IGF-1 levels above what your body would naturally produce, increasing the risk of side effects like insulin resistance, joint pain, and fluid retention.
Tesamorelin takes the indirect route. By stimulating your pituitary to make its own growth hormone, it keeps the natural braking system in place. When IGF-1 levels climb high enough, the pituitary reduces its own output. This is why researchers have found that GHRH analogs like tesamorelin tend to cause fewer metabolic side effects than direct growth hormone therapy, particularly when it comes to blood sugar disruption.
In healthy men, tesamorelin increased IGF-1 levels by an average of 181 micrograms per liter, a significant boost, but one that remains subject to the body’s own regulatory checks. That self-limiting quality is the core pharmacological advantage over both exogenous growth hormone and anabolic steroids, neither of which preserve the body’s feedback mechanisms in the same way.